Ake­bia touts new da­ta on ane­mia drug a year af­ter re­jec­tion

Ake­bia Ther­a­peu­tics is back with more da­ta on its ex­per­i­men­tal ane­mia drug vadadu­s­tat fol­low­ing a CRL from the FDA last year and the end of its part­ner­ship with Ot­su­ka.

The biotech an­nounced on Mon­day that vadadu­s­tat proved non-in­fe­ri­or to Roche and Vi­for’s long-act­ing ery­thro­poiesis-stim­u­lat­ing agent (ESA) Mircera when ad­min­is­tered three times a week for the main­te­nance treat­ment of ane­mia in pa­tients on dial­y­sis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER